MX2022009860A - Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion. - Google Patents

Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion.

Info

Publication number
MX2022009860A
MX2022009860A MX2022009860A MX2022009860A MX2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A
Authority
MX
Mexico
Prior art keywords
polypeptides
infection
treat
compositions
limit development
Prior art date
Application number
MX2022009860A
Other languages
English (en)
Inventor
Neil P King
Carl Walkey
David Veesler
Alexandra C Walls
Jing Yang Wang
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2022009860A publication Critical patent/MX2022009860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

En la presente descripción se describen polipéptidos que comprenden una secuencia de aminoácidos al menos 95 %, al menos 96 %, al menos 97 %, al menos 98 %, al menos 99 % o al menos 100 % idéntica a la secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NOS:1-84, 138-146 y 167-184, nanopartículas de los mismos, composiciones de nanopartículas relacionadas y su uso para tratar o limitar el desarrollo de una infección.
MX2022009860A 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion. MX2022009860A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US202063064235P 2020-08-11 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
MX2022009860A true MX2022009860A (es) 2022-11-07

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009860A MX2022009860A (es) 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion.

Country Status (11)

Country Link
EP (1) EP4103230A1 (es)
JP (1) JP2023513720A (es)
KR (1) KR20220142472A (es)
CN (1) CN116096404A (es)
AU (1) AU2021221139A1 (es)
BR (1) BR112022016220A2 (es)
CA (1) CA3167318A1 (es)
CO (1) CO2022011467A2 (es)
MX (1) MX2022009860A (es)
PE (1) PE20230301A1 (es)
WO (1) WO2021163438A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
WO2023086961A1 (en) * 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571A (zh) * 2022-02-18 2022-06-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
WO2024014943A1 (ko) * 2022-07-12 2024-01-18 에스케이바이오사이언스 주식회사 Sars-cov-2 백신 부스터 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US10676511B2 (en) * 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain

Also Published As

Publication number Publication date
WO2021163438A1 (en) 2021-08-19
AU2021221139A1 (en) 2022-09-01
EP4103230A1 (en) 2022-12-21
CN116096404A (zh) 2023-05-09
CA3167318A1 (en) 2021-08-19
KR20220142472A (ko) 2022-10-21
CO2022011467A2 (es) 2022-10-31
BR112022016220A2 (pt) 2022-10-25
PE20230301A1 (es) 2023-02-13
JP2023513720A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
MX2022009860A (es) Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion.
ATE519842T1 (de) Trichoderma reesei-glucoamylase und homologe davon
HK1125659A1 (en) Kdr peptides and vaccines comprising the same kdr
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
GB2431404A (en) Peptide
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
BR9914066A (pt) Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
NZ595231A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ATE547523T1 (de) Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
WO2023130022A3 (en) Cystatin rna compositions for tissue engineering
WO2021222633A3 (en) Methods for treating covid-19
MX2022009398A (es) Péptidos cíclicos específicos de receptores unidos a diamina.
MX2020013569A (es) Proteína novedosa con propiedades antiinflamatorias.
DK0811068T3 (da) Humane DNase I varianter
MX2023007406A (es) Composiciones que comprenden ciclotidos y otros peptidos insecticidas y usos de las mismas.
ZA202210882B (en) Anti-fungal polypeptides
WO2022226215A8 (en) NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 CRISPR NUCLEASES
WO2022170216A3 (en) Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases
WO2021110063A8 (en) New conjugates of peptides and polysaccharide
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call